Skin and soft tissue infections due to rapidly growing mycobacteria: Comparison of clinical features, treatment, and susceptibility

Daniel Z. Uslan, Todd J. Kowalski, Nancy L. Wengenack, Abinash Virk, John W. Wilson

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Objective: To compare the demographics, clinical features, susceptibility patterns, and treatment for skin and soft tissue infections due to Mycobacterium fortuitum and Mycobacterium chelonae or Mycobacterium abscessus. Design: Retrospective medical record review. Setting: Mayo Clinic, Rochester, Minn. Patients: All patients seen at our institution with a positive culture for M chelonae, M abscessus, or M fortuitum from skin or soft tissue sources between January 1, 1987, and October 31, 2004. Main Outcome Measures: Patient demographics, clinical characteristics, therapeutic data, microbiological data, and outcomes. Results: The medical records of 63 patients with skin or soft tissue infections due to rapidly growing mycobacteria were reviewed. Patients with M chelonae or Mabscessus were older (61.5 vs 45.9 years, P<.001) and more likely to be taking immunosuppressive medications (60% vs 17%, P=.002) than patients with M fortuitum. Mycobacterium fortuitum tended to manifest as a single lesion (89% vs 38%, P<.001), while most M chelonae or M abscessus manifested as multiple lesions (62% vs 11%, P<.001). More patients with M fortuitum had a prior invasive surgical procedure at the infected site (56% vs 27%, P=.04). Patients with multiple lesions were more likely to be taking immunosuppressive medications than those with single lesions (67% vs 30%, P=.006). Seven patients failed treatment, several of whom were immunocompromised and had multiple comorbidities. Conclusions: Skin and soft tissue infections due to rapidly growing mycobacteria are associated with systemic comorbidities, including the use of immunosuppressive medications. There are significant differences in the demographic and clinical features of patients who acquire specific organisms, including association with immunosuppression and surgical procedures.

Original languageEnglish (US)
Pages (from-to)1287-1292
Number of pages6
JournalArchives of Dermatology
Volume142
Issue number10
StatePublished - 2006

Fingerprint

Soft Tissue Infections
Mycobacterium
Skin
Immunosuppressive Agents
Mycobacterium fortuitum
Therapeutics
Demography
Medical Records
Comorbidity
Mycobacterium chelonae
Immunosuppression
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Dermatology

Cite this

Uslan, D. Z., Kowalski, T. J., Wengenack, N. L., Virk, A., & Wilson, J. W. (2006). Skin and soft tissue infections due to rapidly growing mycobacteria: Comparison of clinical features, treatment, and susceptibility. Archives of Dermatology, 142(10), 1287-1292.

Skin and soft tissue infections due to rapidly growing mycobacteria : Comparison of clinical features, treatment, and susceptibility. / Uslan, Daniel Z.; Kowalski, Todd J.; Wengenack, Nancy L.; Virk, Abinash; Wilson, John W.

In: Archives of Dermatology, Vol. 142, No. 10, 2006, p. 1287-1292.

Research output: Contribution to journalArticle

Uslan, DZ, Kowalski, TJ, Wengenack, NL, Virk, A & Wilson, JW 2006, 'Skin and soft tissue infections due to rapidly growing mycobacteria: Comparison of clinical features, treatment, and susceptibility', Archives of Dermatology, vol. 142, no. 10, pp. 1287-1292.
Uslan, Daniel Z. ; Kowalski, Todd J. ; Wengenack, Nancy L. ; Virk, Abinash ; Wilson, John W. / Skin and soft tissue infections due to rapidly growing mycobacteria : Comparison of clinical features, treatment, and susceptibility. In: Archives of Dermatology. 2006 ; Vol. 142, No. 10. pp. 1287-1292.
@article{a2b4de9622ab43b78547f49bb4aa7f1d,
title = "Skin and soft tissue infections due to rapidly growing mycobacteria: Comparison of clinical features, treatment, and susceptibility",
abstract = "Objective: To compare the demographics, clinical features, susceptibility patterns, and treatment for skin and soft tissue infections due to Mycobacterium fortuitum and Mycobacterium chelonae or Mycobacterium abscessus. Design: Retrospective medical record review. Setting: Mayo Clinic, Rochester, Minn. Patients: All patients seen at our institution with a positive culture for M chelonae, M abscessus, or M fortuitum from skin or soft tissue sources between January 1, 1987, and October 31, 2004. Main Outcome Measures: Patient demographics, clinical characteristics, therapeutic data, microbiological data, and outcomes. Results: The medical records of 63 patients with skin or soft tissue infections due to rapidly growing mycobacteria were reviewed. Patients with M chelonae or Mabscessus were older (61.5 vs 45.9 years, P<.001) and more likely to be taking immunosuppressive medications (60{\%} vs 17{\%}, P=.002) than patients with M fortuitum. Mycobacterium fortuitum tended to manifest as a single lesion (89{\%} vs 38{\%}, P<.001), while most M chelonae or M abscessus manifested as multiple lesions (62{\%} vs 11{\%}, P<.001). More patients with M fortuitum had a prior invasive surgical procedure at the infected site (56{\%} vs 27{\%}, P=.04). Patients with multiple lesions were more likely to be taking immunosuppressive medications than those with single lesions (67{\%} vs 30{\%}, P=.006). Seven patients failed treatment, several of whom were immunocompromised and had multiple comorbidities. Conclusions: Skin and soft tissue infections due to rapidly growing mycobacteria are associated with systemic comorbidities, including the use of immunosuppressive medications. There are significant differences in the demographic and clinical features of patients who acquire specific organisms, including association with immunosuppression and surgical procedures.",
author = "Uslan, {Daniel Z.} and Kowalski, {Todd J.} and Wengenack, {Nancy L.} and Abinash Virk and Wilson, {John W.}",
year = "2006",
language = "English (US)",
volume = "142",
pages = "1287--1292",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Skin and soft tissue infections due to rapidly growing mycobacteria

T2 - Comparison of clinical features, treatment, and susceptibility

AU - Uslan, Daniel Z.

AU - Kowalski, Todd J.

AU - Wengenack, Nancy L.

AU - Virk, Abinash

AU - Wilson, John W.

PY - 2006

Y1 - 2006

N2 - Objective: To compare the demographics, clinical features, susceptibility patterns, and treatment for skin and soft tissue infections due to Mycobacterium fortuitum and Mycobacterium chelonae or Mycobacterium abscessus. Design: Retrospective medical record review. Setting: Mayo Clinic, Rochester, Minn. Patients: All patients seen at our institution with a positive culture for M chelonae, M abscessus, or M fortuitum from skin or soft tissue sources between January 1, 1987, and October 31, 2004. Main Outcome Measures: Patient demographics, clinical characteristics, therapeutic data, microbiological data, and outcomes. Results: The medical records of 63 patients with skin or soft tissue infections due to rapidly growing mycobacteria were reviewed. Patients with M chelonae or Mabscessus were older (61.5 vs 45.9 years, P<.001) and more likely to be taking immunosuppressive medications (60% vs 17%, P=.002) than patients with M fortuitum. Mycobacterium fortuitum tended to manifest as a single lesion (89% vs 38%, P<.001), while most M chelonae or M abscessus manifested as multiple lesions (62% vs 11%, P<.001). More patients with M fortuitum had a prior invasive surgical procedure at the infected site (56% vs 27%, P=.04). Patients with multiple lesions were more likely to be taking immunosuppressive medications than those with single lesions (67% vs 30%, P=.006). Seven patients failed treatment, several of whom were immunocompromised and had multiple comorbidities. Conclusions: Skin and soft tissue infections due to rapidly growing mycobacteria are associated with systemic comorbidities, including the use of immunosuppressive medications. There are significant differences in the demographic and clinical features of patients who acquire specific organisms, including association with immunosuppression and surgical procedures.

AB - Objective: To compare the demographics, clinical features, susceptibility patterns, and treatment for skin and soft tissue infections due to Mycobacterium fortuitum and Mycobacterium chelonae or Mycobacterium abscessus. Design: Retrospective medical record review. Setting: Mayo Clinic, Rochester, Minn. Patients: All patients seen at our institution with a positive culture for M chelonae, M abscessus, or M fortuitum from skin or soft tissue sources between January 1, 1987, and October 31, 2004. Main Outcome Measures: Patient demographics, clinical characteristics, therapeutic data, microbiological data, and outcomes. Results: The medical records of 63 patients with skin or soft tissue infections due to rapidly growing mycobacteria were reviewed. Patients with M chelonae or Mabscessus were older (61.5 vs 45.9 years, P<.001) and more likely to be taking immunosuppressive medications (60% vs 17%, P=.002) than patients with M fortuitum. Mycobacterium fortuitum tended to manifest as a single lesion (89% vs 38%, P<.001), while most M chelonae or M abscessus manifested as multiple lesions (62% vs 11%, P<.001). More patients with M fortuitum had a prior invasive surgical procedure at the infected site (56% vs 27%, P=.04). Patients with multiple lesions were more likely to be taking immunosuppressive medications than those with single lesions (67% vs 30%, P=.006). Seven patients failed treatment, several of whom were immunocompromised and had multiple comorbidities. Conclusions: Skin and soft tissue infections due to rapidly growing mycobacteria are associated with systemic comorbidities, including the use of immunosuppressive medications. There are significant differences in the demographic and clinical features of patients who acquire specific organisms, including association with immunosuppression and surgical procedures.

UR - http://www.scopus.com/inward/record.url?scp=33750057970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750057970&partnerID=8YFLogxK

M3 - Article

C2 - 17043183

AN - SCOPUS:33750057970

VL - 142

SP - 1287

EP - 1292

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 10

ER -